The current status of adjuvant hormonal therapy combined with radiation therapy for localised prostate cancer
Material type:![Text](/opac-tmpl/lib/famfamfam/BK.png)
- Analysis of the results of treatment of localised prostate cancer with radiation and surgery has identified patients who are at high risk of developing metastatic dissemination. High histologic grade, serum prostate specific antigen above 20 ng/ml, extension beyond the capsule of the prostate, and involvement of lymph nodes are highly predictive of metastatic risk. Antiandrogen therapy has high rates of activity in the treatment of overt metastatic disease prompting its assessment as an adjuvant treatment added to radiation therapy. There are now major prospective randomized trials which have been completed. The current evidence indicates that a large survival benefit ensues when antiandrogen therapy is added to radiation for appropriately selected patients. This adjuvant approach is likely to become the standard of care. Strategies for further enhancement of adjuvant therapy are discussed
- Publications Archive ARMS
Item type | Current library | Home library | Shelving location | Call number | Status | Date due | Barcode | Item holds | |
---|---|---|---|---|---|---|---|---|---|
2 Week Loan | St. Luke’s Radiation Oncology Network Dublin | St. Luke’s Radiation Oncology Network Dublin | AR | PUBLICATIONS ARCHIVE ARMS (Browse shelf(Opens below)) | Available | 39015000018328 |
Total holds: 0
The print version of this article is held in the Oncology Resource Centre.
There are no comments on this title.
Log in to your account to post a comment.